Far Infrared Therapy May Improve Arterial Insufficiency and Joint Inflammation in CKD Stage 5 Patients

February 12, 2020

Introduction

Far infrared (FIR) induces expression of endothelial heme oxygenase-1, reduces monocyte adhesion to endothelial cells, and provides a strong anti-inflammatory benefit to the vascular endothelium. It has been shown that FIR therapy improves to the vascular endothelium. It has been shown that FIR therapy improves dialysis fistula flow, maturation, and patency and leads to decrease pain and hematoma formation with needling in CKD stage 5 and 5d patients. It is also effective in relieving pain in patients with chronic pain syndromes like fibromyalgia and phantom limb after amputation through thermal and non-thermal effects. In the past we reported an improvement in graft stenosis and resolution of internal jugular vein thrombus associated with tunneled catheter insertion in two dialysis patients with FIR therapy. Now we report 3 CKD stage 5 patients with improvement of arterial insufficiency, frozen shoulder and partial rotator cuff injury using FIR therapy.

Case description

Case 1

A 68 year old man with CKD 5 due to FSGS and HTN developed significant claudication on his right leg and discoloration of his second toe. An arteriogram showed substantial small arterial disease not amenable to bypass and below knee amputation was recommended by his surgeon. A trial of FIR therapy on his leg was done, and after three weeks, claudication and toe discoloration resolved. FIR therapy was stopped and he remained pain free after 2 years of follow-up.

Case 2

A 67 year old man with CKD 5d due to HTN developed left shoulder pain with restricted range of motion. Analgesics and 3 weeks of physical therapy (PT) did not provide relief. A trial of 40 minutes of FIR therapy 3 times a week during dialysis was done. After 3 weeks, his frozen shoulder improved completely.

Case 3

A 75 year old woman with CKD 5 developed right partial rotator cuff tear after a fall. Diagnosis was confirmed by MRI and surgery was recommended. She refused surgery and tried 2 months of PT, which did not provide relief. Trial of FIR therapy was done with compete resolution of pain and stiffness after 3 weeks.

Discussion

FIR therapy may have beneficial effect on arterial insufficiency and joint injury and inflammation and should be considered in CKD 5 patients suffering from these conditions. It is non-invasive and can be easily done as 40-minute sessions in the clinic or during dialysis treatments

a Independent t test; b Chi-square test; c Fisher's exact test; d Mann-Whitney test

Author's:

  • S Akbar,
  • C Irene Mejia
  • R Ullah
  • S Humaria
  • Z Ahmed
  • R Faruq
  • H Arif


Site:

  • Nephrology and Hypertension, Drexel University College of Medicine, Philadelphia
  • Drexel University College of Medicine, Philadelphia
  • Drexel University, Philadelphia

Presented at the 2019 ASN Conference.

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
May 23, 2025
We’re excited to announce that FIRAPY will be exhibiting at the 62nd ERA Congress in Vienna from June 4–7, 2025 ! 📍 Booth No.: X1.200 📅 June 4–7, 2025 📍 Austria Center Vienna This marks FIRAPY’s first European event since the COVID-19 pandemic , making it a special occasion for us to reconnect with partners and professionals across the continent. This year’s congress theme, “Game Changers in Nephrology,” aligns perfectly with FIRAPY’s mission to enhance dialysis care through innovative vascular access management. We look forward to seeing old friends and new collaborators who share our commitment to improving outcomes for dialysis patients. Whether you're already using FIRAPY or exploring its clinical potential, we warmly invite you to visit our booth and connect with our team.  Let’s explore how far-infrared therapy is transforming the future of vascular access—together.
May 23, 2025
From February 28 to March 1, FIRAPY was honored to participate in Dialysis Weekend 2024 in Pattaya, Thailand, at the invitation of our valued partner K2 Thailand . This annual event, hosted by the Nephrology Society of Thailand ( event site ), is a key gathering for nephrology professionals across the country. This occasion marked a milestone for K2 Thailand, as their entire dialysis sales team made their first collective public appearance alongside FIRAPY. The team’s strong presence and professionalism drew significant attention from both clinicians and industry attendees, highlighting the growing interest in FIRAPY's role in dialysis care. A special highlight of the event was the visit from Dr. Suki , a well-known figure in the international nephrology community ( WCN profile ). Dr. Suki stopped by the K2 booth to personally show support and encouragement to the team, reinforcing the collaboration and shared mission of improving vascular access outcomes for dialysis patients. 
December 2, 2024
Meet FIRAPY at Booth i1115a!
More Posts